SAN DIEGO, Feb. 3 /PRNewswire-FirstCall/ -- Gen-Probe Incorporated announced today that the Company will present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device in New York on February 8, 2005 at approximately 11:15 a.m. Eastern Time. The presentation is scheduled to be webcast live and may be accessed through a link on the investor relations section of Gen-Probe’s website at http://www.gen-probe.com/. The webcast will be available for 14 days following the event.
About Gen-Probe
Gen-Probe Incorporated is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective nucleic acid tests for diagnosing human diseases and screening donated human blood. Using its patented technologies, Gen-Probe has received FDA approvals or clearances for a broad portfolio of products that detect a variety of infectious microorganisms, including those causing sexually transmitted diseases, tuberculosis, strep throat, pneumonia and fungal infections. In addition, Gen-Probe’s TIGRIS(R) instrument is the only fully automated, high-throughput system in the molecular diagnostics industry. The Company also developed and manufactures the only FDA-approved blood-screening assay for the simultaneous detection of HIV-1 and HCV, which is marketed by Chiron Corporation. Gen-Probe has more than 20 years of nucleic acid detection research and product development experience, and its products are used daily in clinical laboratories and blood collection centers throughout the world. Gen-Probe is headquartered in San Diego, California and employs approximately 900 people. For more information, go to http://www.gen-probe.com/.
Caution Regarding Forward-Looking Statements
Any statements in this press release about our expectations, beliefs, plans, objectives, assumptions or future events or performance, including those relating to the use and effectiveness of our products and our collaborations and other agreements with third parties to develop, manufacture and market our products, are not historical facts and are forward-looking statements. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by any forward-looking statement. For information about risks and uncertainties we face and a discussion of our financial statements and footnotes, see documents we have filed with the SEC, including the Form 10-Q for the quarter ended September 30, 2004, and all subsequent periodic fillings made with the SEC. We assume no obligation and expressly disclaim any duty to update any forward-looking statement to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.
Contact: Paula Izidoro Investor Relations 858-410-8904
Gen-Probe Incorporated
CONTACT: Paula Izidoro, Investor Relations of Gen-Probe Incorporated,+1-858-410-8904
Web site: http://www.gen-probe.com/
